Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 July 2019 | Story Valentino Ndaba
Prof Dave Lubbe
Winner of the Southern African Accounting Association Lifetime Achievement Award, Prof Dave Lubbe, has lived a life full of achievements.

The highest body of professional academic accountants in the country, the Southern African Accounting Association (SAAA), recently honoured Prof Dave Lubbe with the prestigious Lifetime Achievement Award at a gala dinner at Emperors Palace in Johannesburg. Prof Lubbe is a Research Associate and an Emeritus Professor at the School of Accountancy at the University of the Free State (UFS).

The SAAA honoured him “for his distinguished service and valuable contribution to accounting education in South Africa”. He was recognised for his contributions to audit committees in the private and public sectors, environmental accounting and auditing, the philosophy of auditing, audit risk and the expectation gap between the audit profession and users of financial information. 
     
A friend of firsts

Prof Lubbe was the first person to attain a doctorate in Auditing in South Africa, the first to author an Afrikaans auditing handbook, the first South African recipient of the Ernst & Young Outstanding Accounting Research Award in 2002 and the first Chartered Accountant to be awarded the Stals Prize for Economic and Management Sciences by the South African Academy for Science and Arts in 2007.  

His astounding track record also earned him the university’s 2018 Executive Management Award at the 36th Chancellor’s Distinguished Alumni Awards. Not only is he a former master’s student at the university, but he also went on to serve as a senior lecturer for 41 years.

Called to serve

In his lifetime, Prof Lubbe has answered the call to serve as a management consultant, committee member, a forensic accountant, and an assessor to high court fraud cases. 

Beyond the field of accounting
 

His achievements span beyond the accounting field. Not only has Prof Lubbe completed all of South Africa’s well-known ultramarathons, he holds a black belt in karate. His love for art on the other hand, has seen him win national poetry competitions and establishing himself as a lyricist.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept